Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), a biopharmaceutical company focused on first-in-class critical care products, announced its first reported revenue after the successful launch of LYMPHIR™. The company generated $3.9 million in revenue from initial sales in December 2025 and shared its financial results for the fiscal first quarter ending December 31, 2025.
Transitioning to a Revenue-Generating Company
Leonard Mazur, Chairman and CEO of both Citius Oncology and Citius Pharma, expressed excitement about this milestone. “We have successfully transitioned to a revenue-generating company with the launch of LYMPHIR. The $3.9 million in revenue reflects the hard work of our team and our commitment to delivering value to the cutaneous T-cell lymphoma (CTCL) community and our stakeholders,” Mazur stated.
He added that while the launch is still in its early stages, the company expects momentum to grow as it builds out its commercial organization and deploys its technology-driven platform to expand patient access and market penetration.
LYMPHIR Launch Highlights
Citius Oncology, a majority-owned subsidiary of Citius Pharma, launched LYMPHIR™ (denileukin diftitox-cxdl) in December 2025. The FDA-approved targeted immunotherapy is designed for adult patients with relapsed or refractory Stage I–III CTCL who have undergone at least one prior systemic therapy.
The launch has already seen early physician adoption, with specialty distributor sales completed nationwide. Leading cancer centers across the U.S. have begun administering LYMPHIR to patients. To support its commercial efforts, Citius Oncology deployed an AI-enabled platform to engage physicians and efficiently penetrate the rare oncology market.
Expanding International Access and Clinical Opportunities
Citius Oncology is also advancing international access to LYMPHIR. The company has negotiated agreements with regional partners to enable patient access through Named Patient Programs (NPPs) in Europe and the Middle East.
Additionally, the company is exploring opportunities to expand LYMPHIR’s clinical utility. Preliminary data from two investigator-initiated Phase I combination studies show promise. These studies include LYMPHIR’s use with pembrolizumab for recurrent solid tumors and its incorporation into lymphodepletion regimens before CAR-T therapy.
Pipeline Progress and Financial Stewardship
Beyond LYMPHIR, Citius Pharma continues to advance its late-stage pipeline. The company is actively working with the FDA on next steps for Mino-Lok®, an antibiotic lock solution for catheter-related bloodstream infections, and Halo-Lido (CITI-002), a topical prescription formulation for hemorrhoids. Both programs have completed pivotal trials, with Mino-Lok meeting its primary and secondary endpoints in Phase 3.
Mazur emphasized the company’s commitment to financial stewardship. “We remain focused on advancing our late-stage pipeline while maximizing long-term shareholder value,” he said.
First Quarter 2026 Financial Results
Citius Pharma reported several key financial highlights for the quarter ending December 31, 2025:
- Revenue: $3.9 million from initial LYMPHIR sales.
- Cash and Cash Equivalents: $7.7 million as of December 31, 2025.
- Equity Financing: Net proceeds of $20.9 million raised during the quarter.
- Research and Development Expenses: $1.6 million, down from $2.1 million in the prior-year period.
- General and Administrative Expenses: $5.7 million, compared to $5.4 million in the prior year.
- Net Loss: $8.2 million, or $(0.41) per share, compared to $9.8 million, or $(1.30) per share, in the prior year.
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is dedicated to developing and commercializing first-in-class critical care products. The company owns 74.8% of Citius Oncology, which launched LYMPHIR in December 2025. Citius Pharma’s pipeline includes Mino-Lok®, a catheter lock solution, and Halo-Lido, a topical treatment for hemorrhoids. For more information, visit www.citiuspharma.com.
About Citius Oncology, Inc.
Citius Oncology, Inc. (Nasdaq: CTOR) focuses on developing and commercializing targeted oncology therapies. LYMPHIR, its FDA-approved immunotherapy, addresses a growing market for relapsed or refractory CTCL. Management estimates the initial market for LYMPHIR exceeds $400 million and continues to grow. For more information, visit www.citiusonc.com.
This milestone marks a significant step forward for Citius Pharmaceuticals as it transitions into a revenue-generating company while advancing its mission to deliver innovative critical care solutions.
The post Citius Pharmaceuticals Reports First Revenue Following LYMPHIR™ Launch appeared first on PRISM MarketView.